drugset / Trial / NCT00364091

Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

NCT00364091

Phase 3 Completed 365 enrolled Vistakon Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis

Timeline

Start
2006-08
Primary completion
2006-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcaftadine Small molecule 0.025 % Other

Indications